I-Mab

NASDAQ:

IMAB

I-Mab is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. I-Mab's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on its unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. I-Mab is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States.

Key Facts

Auditor

Public Listing

Domicile

HQ/Management

Location of Key Operations

IR Contact

Pricewaterhousecoopers Zhong Tian LLP

IPO (January 17, 2020)

Cayman Islands

Shanghai, China

Shanghai, HK, US

Jielun Zhu, Internal

86-21-6057-8000

Analyst Coverage

Latest News